Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 64,600 shares, a growth of 119.0% from the May 15th total of 29,500 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 643,400 shares, the short-interest ratio is presently 0.1 days.
Analysts Set New Price Targets
Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th.
Check Out Our Latest Report on Daiichi Sankyo
Daiichi Sankyo Stock Performance
DSNKY traded down $0.39 on Monday, hitting $24.21. 141,674 shares of the stock traded hands, compared to its average volume of 263,462. Daiichi Sankyo has a 52 week low of $20.92 and a 52 week high of $42.48. The firm has a market capitalization of $45.87 billion and a PE ratio of 28.15. The business has a fifty day moving average price of $24.62 and a two-hundred day moving average price of $25.58. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06.
Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $0.30 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. The company had revenue of $3.40 billion for the quarter. On average, research analysts predict that Daiichi Sankyo will post 0.73 EPS for the current fiscal year.
Daiichi Sankyo Company Profile
(
Get Free Report)
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.
Further Reading
Before you consider Daiichi Sankyo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.
While Daiichi Sankyo currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
